Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.56 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5686248 | 0.90 | MAPT (0.53) | GPR119PDK2MAPTALDH1A1LMNA | |
| SCHEMBL7078017 | 0.87 | MAPT (0.60) | GPR119PDK2MAPTALDH1A1LMNA | |
| SCHEMBL5683363 | 0.86 | LMNA (0.50) | GPR119PDK2MAPTALDH1A1LMNA | |
| SCHEMBL29556504 | 0.86 | ABCB1 (0.59) | GPR119PDK2MAPTALDH1A1LMNA | |
| SCHEMBL2385957 | 0.86 | ABCB1 (0.59) | GPR119PDK2MAPTALDH1A1LMNA | |
| SCHEMBL31466327 | 0.84 | RET (0.46) | GPR119MAPTLMNAPDE4DKDM4E | |
| Tert-Butanol SCHEMBL6417410 | 0.84 | KDM4E (0.48) | ALDH1A1LMNAKDM4ERECQLFAAH | |
| SCHEMBL2386747 | 0.83 | GPR119 (0.59) | GPR119PDK2MAPTALDH1A1LMNA | |
| SCHEMBL25317395 | 0.83 | GPR119 (0.62) | GPR119PDK2MAPTALDH1A1LMNA | |
| SCHEMBL29475574 | 0.83 | GPR119 (0.62) | GPR119PDK2MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AVENTIS PHARMA S. A. (FR) | 2005-06-16 | — | — | US | disclosed |
| US-20050014765-A1 | Aryl-heteroaromatic products, compositions comprising them and use | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014765-A1 | Aryl-heteroaromatic products, compositions comprising them and use | AHR, ARNT, MYC | GPR119 3382/4885PDK2 1230/4885MAPT 3583/4885 |
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AHR, NQO1, ARNT | GPR119 2889/4885PDK2 1368/4885MAPT 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.